MO436PLASMA OXALATE VALUES IN PATIENTS WITH END-STAGE KIDNEY DISEASE
Ella Metry(Emma Kinderziekenhuis), Jaap W. Groothoff(University of Amsterdam), Aegida Neradová(Dianet), Joost A. Bijlsma(Dianet), Sander F. Garrelfs(Emma Kinderziekenhuis), Michiel J.S. Oosterveld(Emma Kinderziekenhuis), Frédéric M. Vaz(Netherlands Metabolomics Centre)
Cited by 0
Related Papers
Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies
|Nature Medicine|2014|843
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1
|New England Journal of Medicine|2021|509
Primary hyperoxaluria Type 1: indications for screening and guidance for diagnosis and treatment
|Nephrology Dialysis Transplantation|2012|335
Mutations in LPIN1 Cause Recurrent Acute Myoglobinuria in Childhood
|The American Journal of Human Genetics|2008|218
Clinical practice recommendations for primary hyperoxaluria: an expert consensus statement from ERKNet and OxalEurope
|Nature Reviews Nephrology|2023|154